Development of a lactylation-related molecular classification and machine learning-based gene signature to predict survival, response to immunotherapy for ovarian cancer
Lactylation is acknowledged as a regulator of numerous biological processes related to cancer. Research on the ability of lactylation-related genes (LacRGs) to predict prognosis and immunotherapeutic response in ovarian cancer (OC) patients is limited. Consensus clustering was utilized to identify prognostic differentially expressed genes (DEGs) across clusters. A consensus lactylation-related gene signature (LRGS) was established from TCGA-OC and four independent GSE datasets through a machine learning-based integrative approach. LRGS demonstrates consistent and robust performance as an independent risk factor for overall survival. Furthermore, while the low-LRGS group is more likely to exhibit the "hot tumor" phenotype, it also shows a more favorable prognosis and enhanced responsiveness to immunotherapy. Patients exhibiting a high LRGS demonstrated a reduced probability of deriving benefit from immunotherapy and faced a poor prognosis. The oncogenic role of the risk gene RPS6KA2 was preliminarily validated. An in-depth analysis of the LacRGs data may yield valuable insights and enhance the molecular classification of OC. The identification of LRGS serves as a crucial factor in the early prognosis of patients and the selection of potential candidates for immunotherapy. The findings have significant implications for individual patients with OC.